Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$45.69

-3.67 (-7.44%)

, CELG

Celgene

$93.48

-5.44 (-5.50%)

09:12
06/25/19
06/25
09:12
06/25/19
09:12

Bristol-Myers sentiment suffered 'double hit' yesterday, says William Blair

William Blair analyst Matt Phipps said Bristol-Myers (BMY) suffered a "double hit to sentiment" yesterday with the news of both the CheckMate-459 trial failure in first-line hepatocellular carcinoma and delay of the closing of its Celgene (CELG) deal due to the required Otezla divestiture. He had previously modeled Opdivo sales in the front-line setting of over $1B and Otezla sales growing to $3B before loss of exclusivity in 2028 and decreased his out-year EPS estimates by over $1.00 due to yesterday's news. However, although near-term sentiment is dampened, he still sees a long-term opportunity, said Phipps, who keeps an Outperform rating on Bristol-Myers shares.

BMY

Bristol-Myers

$45.69

-3.67 (-7.44%)

CELG

Celgene

$93.48

-5.44 (-5.50%)

  • 27

    Jun

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

BMY Bristol-Myers
$45.69

-3.67 (-7.44%)

06/24/19
CANT
06/24/19
NO CHANGE
Target $100
CANT
Neutral
Celgene pushback surprising, but deal should still close, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young said she was surprised by the FTC pushback around Otezla and its overlap in psoriasis related to Celgene's (CELG) oral TYK2 program BMS-986165 in psoriasis given that the latter has not yet reported Phase 3 data. After speaking to Bristol-Myers (BMY), Young said management was also disappointed in this FTC decision, which they said was not related to current asset Orencia marketed for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Though timelines are delayed, she still sees "a high likelihood" that the deal closes, but potentially 4-6 months behind schedule. Young, who sees many players in Inflammation & Immunology that could leverage oral Otezla with their existing salesforce, added that Bristol may not lose much in value from this divestiture if the process is competitive. She keeps a Neutral rating and $100 price target on Celgene shares.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
05/28/19
GSCO
05/28/19
DOWNGRADE
Target $60
GSCO
Sell
Goldman sees negative sales growth for Gilead, downgrades shares to Sell
Goldman Sachs analyst Terence Flynn downgraded Gilead Sciences (GILD) to Sell from Neutral and lowered his price target for the shares to $60 from $70. The analyst expects Gilead's sales growth to decelerate saying the Truvada/Atripla loss of exclusivities in Sept ember 2020 represents a $3B headwind. Further, Biktarvy can only protect about half of the company's $16B HIV franchise from generic competition, Flynn tells investors in a research note. As a result, the analyst models annual revenue growth for Gilead through 2022 as negative 5%, which he notes is among the lowest in his coverage universe. Meanwhile, the stock trades at a slight premium to other stocks such as Bristol-Myers (BMY) and AbbVie (ABBV), says Flynn.
05/28/19
GSCO
05/28/19
INITIATION
Target $54
GSCO
Buy
Bristol-Myers initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Bristol-Myers Squibb with a Buy rating and $54 price target. Bristol-Myers is trading at a "significant discount to the group," Flynn tells investors in a research note. The analyst says his call is based on valuation, and he sees potential for multiple expansion whether or not the Celgene (CELG) acquisition closes.
CELG Celgene
$93.48

-5.44 (-5.50%)

05/20/19
05/20/19
DOWNGRADE

Hold
Bristol-Myers downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded Bristol-Myers (BMY) to Hold from Buy, saying he has "serious concerns" about the company's growth prospects after its announced acquisition of Celgene (CELG). The analyst contends that Celgene's pipeline is not sufficient to offset the expected decline in revenues from its Revlimid, which will lose exclusivity in 2026. Toung adds that Bristol-Myers' "patent cliff" is also notable with loss of exclusivity expected for Opdivo in 2028, Eliquis in 2026, and Orencia in 2021. While the stock trades at 10.5-times forward earnings multiple - a discount to the 12-times peer group average - the analyst believes the valuation is appropriate.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $23
PIPR
Overweight
Sutro regaining U.S. rights from Celgene a 'clear positive,' says Piper Jaffray
The FDA has cleared the investigational new drug application for Sutro Biopharma's Celgene-partnered BCMA ADC, which is on track to enter the clinic in 2019, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. In addition, Celgene not exercise an option on a second program, meaning Sutro has regained U.S. rights, adds the analyst. He views this as a "clear positive" for Sutro, saying the company has regained the U.S. rights to "another exciting preclinical program." Importantly, there is no impact on Sutro's wholly-owned clinical programs, Tenthoff adds. He reiterates an Overweight rating on Sutro Biopharma with a $23 price target.

TODAY'S FREE FLY STORIES

WMT

Walmart

$114.83

0.15 (0.13%)

12:36
07/19/19
07/19
12:36
07/19/19
12:36
Periodicals
Walmart to shuffle executives to further integrate stores and digital, CNBC says »

CNBC's Courtney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 25

    Sep

  • 13

    Nov

NFLX

Netflix

$321.59

-3.55 (-1.09%)

12:29
07/19/19
07/19
12:29
07/19/19
12:29
Periodicals
Eddie Murphy in talks with Netflix over comedy specials, TMZ reports »

Comedian and actor Eddie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

FL

Foot Locker

$42.72

0.35 (0.83%)

12:25
07/19/19
07/19
12:25
07/19/19
12:25
Options
Foot Locker call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 19

    Sep

  • 25

    Sep

DIS

Disney

$141.00

-0.62 (-0.44%)

, SNE

Sony

$53.93

-0.02 (-0.04%)

12:21
07/19/19
07/19
12:21
07/19/19
12:21
On The Fly
Box Office Battle: 'Lion King' expected to claim this weekend's throne »

Welcome to "Box Office…

DIS

Disney

$141.00

-0.62 (-0.44%)

SNE

Sony

$53.93

-0.02 (-0.04%)

T

AT&T

$32.91

-0.185 (-0.56%)

CBS

CBS

$51.32

-0.02 (-0.04%)

CMCSA

Comcast

$44.14

-0.42 (-0.94%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$11.72

0.14 (1.21%)

LGF.B

Lionsgate

$11.05

0.03 (0.27%)

VIA

Viacom

$35.39

0.39 (1.11%)

VIAB

Viacom

$30.79

0.2 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

12:21
07/19/19
07/19
12:21
07/19/19
12:21
Conference/Events
Wolfe Research utilities/midstream analyst to hold a group luncheon »

Utilities & Midstream…

AMRX

Amneal Pharmaceuticals

$3.35

-0.04 (-1.18%)

, BMY

Bristol-Myers

$43.57

-0.47 (-1.07%)

12:18
07/19/19
07/19
12:18
07/19/19
12:18
Hot Stocks
Amneal Pharmaceuticals granted tentative FDA approval of Apremilast »

Amneal Pharmaceuticals…

AMRX

Amneal Pharmaceuticals

$3.35

-0.04 (-1.18%)

BMY

Bristol-Myers

$43.57

-0.47 (-1.07%)

CELG

Celgene

$90.39

-0.51 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 25

    Jul

  • 08

    Aug

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
07/19/19
07/19
12:17
07/19/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
07/19/19
07/19
12:16
07/19/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YGTY

SSLJ.com

$1.18

-0.12 (-9.23%)

12:15
07/19/19
07/19
12:15
07/19/19
12:15
Hot Stocks
Breaking Hot Stocks news story on SSLJ.com »

SSLJ com Ltd (Class A…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$374.39

13.22 (3.66%)

, MSFT

Microsoft

$138.27

1.98 (1.45%)

12:10
07/19/19
07/19
12:10
07/19/19
12:10
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are modestly…

BA

Boeing

$374.39

13.22 (3.66%)

MSFT

Microsoft

$138.27

1.98 (1.45%)

AXP

American Express

$125.00

-3.4 (-2.65%)

GCI

Gannett

$9.62

1.72 (21.77%)

CRWD

Crowdstrike

$83.30

10.55 (14.50%)

SKX

Skechers

$39.35

4.6 (13.24%)

MIK

Michaels

$7.75

-0.62 (-7.41%)

PACB

Pacific Biosciences

$5.23

-0.64 (-10.90%)

ILMN

Illumina

$291.57

-6.97 (-2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 24

    Jul

  • 29

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

CMI

Cummins

$170.04

2.08 (1.24%)

, VWAGY

Volkswagen

$0.00

(0.00%)

12:06
07/19/19
07/19
12:06
07/19/19
12:06
Periodicals
Cummins makes bid for VW's MAN Energy Solutions unit, Reuters says »

Cummins (CMI) has made an…

CMI

Cummins

$170.04

2.08 (1.24%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

SSRM

SSR Mining

$15.69

-0.04 (-0.25%)

12:05
07/19/19
07/19
12:05
07/19/19
12:05
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

12:05
07/19/19
07/19
12:05
07/19/19
12:05
General news
U.S. Data Slate: The week of July 22 »

U.S. Data Slate: The week…

XOM

Exxon Mobil

$74.86

0.02 (0.03%)

12:04
07/19/19
07/19
12:04
07/19/19
12:04
Periodicals
Exxon Mobil starts process of selling Norwegian oil fields, Bloomberg says »

Exxon Mobil has begun the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

CTK

CooTek

$8.54

-0.02 (-0.23%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
CooTek falls -6.6% »

CooTek is down -6.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWY

Chewy

$30.63

-2.16 (-6.59%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
Chewy falls -6.8% »

Chewy is down -6.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$5.29

-1.02 (-16.16%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
QEP Resources falls -16.2% »

QEP Resources is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$39.22

4.47 (12.86%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
Skechers rises 12.6% »

Skechers is up 12.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFS

Intercorp Financial Services

$45.32

(0.00%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
Intercorp Financial Services rises 17.6% »

Intercorp Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

GCI

Gannett

$9.55

1.65 (20.89%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
Gannett rises 21.1% »

Gannett is up 21.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$89.57

1.92 (2.19%)

, NWSA

News Corp.

$13.21

-0.075 (-0.56%)

11:58
07/19/19
07/19
11:58
07/19/19
11:58
On The Fly
Downgrades of News Corp., Alcoa among today's top analyst calls »

Check out today's top…

PM

Philip Morris

$89.57

1.92 (2.19%)

NWSA

News Corp.

$13.21

-0.075 (-0.56%)

MSGN

MSG Networks

$19.70

-0.52 (-2.57%)

AA

Alcoa

$23.31

-0.11 (-0.47%)

MIK

Michaels

$7.73

-0.64 (-7.65%)

BA

Boeing

$373.56

12.39 (3.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Sep

  • 16

    Oct

RCUS

Arcus Biosciences

$8.31

-0.21 (-2.46%)

11:49
07/19/19
07/19
11:49
07/19/19
11:49
Conference/Events
Arcus Biosciences management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 09

    Sep

APO

Apollo Global

$34.96

0.71 (2.07%)

, NTXFY

Natixis

$0.00

(0.00%)

11:48
07/19/19
07/19
11:48
07/19/19
11:48
Periodicals
Apollo approached Coface with buyout offer, Reuters reports »

Apollo Global Management…

APO

Apollo Global

$34.96

0.71 (2.07%)

NTXFY

Natixis

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

YGTY

SSLJ.com

$1.18

-0.12 (-9.23%)

11:47
07/19/19
07/19
11:47
07/19/19
11:47
Hot Stocks
SSLJ.com to withdraw Nasdaq listing »

SSLJ.com Limited…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANF

Abercrombie & Fitch

$18.77

0.15 (0.81%)

11:45
07/19/19
07/19
11:45
07/19/19
11:45
Options
Abercrombie & Fitch call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.